Implicity operates a software-as-a-medical-device platform for remote cardiac monitoring. It ingests transmissions from implantable cardioverter defibrillators, pacemakers and loop recorders of every major manufacturer into one workflow and layers FDA-cleared AI on top of the raw device alerts.
Named modules shown on its site include the ILR ECG Analyzer, AF Alert Management, Patient Connectivity Management, SignalHF predictive AI and a dynamic billing engine. The platform also exposes research and analytics surfaces for academic medical centers and life-science sponsors.
Remote cardiac monitoring is one of the fastest-growing segments of digital cardiology: roughly one million U.S. heart-failure hospitalizations occur each year, and third-party analyses cited by the company projected the U.S. remote-patient-monitoring market above $25 billion by 2028. Ageing populations and device-implant volume keep expanding the transmittable-data base that monitoring software rides on.
The company's own footprint illustrates the runway: from 60,000 patients in 100 facilities in 2022 to 120,000-plus patients daily across 250-plus centers in the U.S., France and Germany by late 2026, with the growth round earmarked for U.S. commercial hiring.
The company holds multiple FDA 510(k) clearances, including SignalHF, described as the first manufacturer-agnostic heart-failure prediction algorithm, and reports a 26 percent reduction in all-cause mortality in its nationwide EVIDENCE-RM study. Its training data access is unusual: it was the first private company authorized to use France's national Health Data Hub.
Commercially, its agnostic design removes the per-manufacturer portal fragmentation that device vendors' own monitoring suites impose on hospitals, and it adds automated reimbursement billing, claimed at 90 percent-plus compliance. The company reported SOC 2 Type II attestation in 2025-2026.
SignalHF is not available for sale in Europe, and the next-generation ILR ECG Analyzer (V2) evaluated at HRS 2026 was not yet FDA-cleared at announcement, so headline accuracy figures trail the commercially cleared product. Device makers also bundle increasingly capable AI in their own portals, compressing the gap that Implicity's second-layer filtering addresses.
In its home market, reimbursement adoption is slow: company leadership reported roughly 600 days between a favorable HAS superiority opinion and actual reimbursement listing, delaying revenue capture from validated clinical evidence.
Implicity sells as B2B SaaS to hospitals, electrophysiology practices and IDTF clinics through demo-request and account-exec motion rather than self-serve signup; login portals are provisioned per customer in the US and EU. Revenue is tied to monitored-patient volume and workflow seats rather than device hardware.
In France, the software is reimbursed under Article L. 162-52 of the Social Security Code once registered, giving the platform a statutory reimbursement pathway; in the U.S. its billing engine is positioned to capture existing CPT-based remote-monitoring reimbursement for providers, which anchors its value proposition.
